Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

In-situ gelation chemotherapy and immunotherapy combined biopolymer pharmaceutical composition

A biopolymer, chemotherapy-immunization technology, which is applied in the field of in-situ gelation chemotherapy-immunity combined therapy drug composition, can solve the problems of side effects and low clinical response rate

Pending Publication Date: 2020-07-07
SUZHOU INNOVATIVE BIOMATERIALS & PHARM CO LTD
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] Although tumor immunotherapy represented by immune checkpoint blockade has made encouraging achievements in recent years, this therapy still has important limitations, including low clinical response rate (about 20%), non-specific immune response side effects etc.
In particular, the low clinical response rate of current clinical immune checkpoint blockade therapy means that most patients do not respond to this expensive therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • In-situ gelation chemotherapy and immunotherapy combined biopolymer pharmaceutical composition
  • In-situ gelation chemotherapy and immunotherapy combined biopolymer pharmaceutical composition
  • In-situ gelation chemotherapy and immunotherapy combined biopolymer pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Example 1: Preparation and use of sodium alginate (the first type of component) and imiquimod (the third type of component) hydrochloride composition freeze-dried powder injection

[0106] Step 1: Preparation of imiquimod (the third component) hydrochloride. Weigh 50-100 mg of imiquimod into a 50 ml glass mixing container, add 1 ml of 1M dilute hydrochloric acid therein, and add deionized water to dilute after the white powdery imiquimod is fully dissolved until it is colorless and transparent, so that The final concentration of imiquimod is 2.5-5 mg / ml. The solution was freeze-dried to obtain freeze-dried powder of imiquimod hydrochloride. The purpose of this step is to convert the water-insoluble imiquimod into the water-soluble hydrochloride form. Sufficient lyophilization time is required to ensure complete removal of hydrochloric acid residues.

[0107] Step 2: The following three methods can be used to prepare the freeze-dried powder injection of the hydrochlor...

Embodiment 2

[0121] Example 2: Sodium alginate (the first type of component) and CpG oligonucleotide (the third type of component) composition freeze-dried powder injection

[0122] Step 1: Preparation of sodium alginate and CpG oligonucleotide composition freeze-dried powder injection

[0123] Weighing 10-80 mg of sodium alginate and 0.1-5 mg of CpG oligonucleotides are dissolved in 1 ml of aqueous phase solution, fully shaken until the solution is clear and transparent, and then freeze-drying the solution to obtain a freeze-dried powder injection of the composition.

[0124] Figure 5 It is a scanning electron microscope picture of the freeze-dried powder injection of the composition after reconstitution into a gel. It can be seen from the figure that the composition still has good gelation ability after freeze-drying and reconstitution, and from the electron microscope pictures, it can be seen that there are many micron-scale pores after gelation, which is of great help to the sustaine...

Embodiment 3

[0133] Embodiment three: Sodium alginate (the first type of component) and doxorubicin hydrochloride (the second type of component) composition freeze-dried powder injection

[0134] Step 1: Preparation of freeze-dried powder injection of sodium alginate and doxorubicin hydrochloride composition:

[0135] Method 1: Weigh 20-80 mg of sodium alginate and 0.1-10 mg of doxorubicin hydrochloride and dissolve them in 1 ml of aqueous phase solution, stir with a stirring paddle at a speed of 50-300 rpm until the solution is clear and transparent, and then dissolve The solution is freeze-dried to obtain a freeze-dried powder injection of the composition.

[0136] Method 2: Dissolve 0.1-10 mg of doxorubicin hydrochloride in 1 ml of aqueous phase solution, stir with a stirring paddle at a speed of 50-300 rpm until the solution is clear and transparent, and then dissolve 10-80 mg of sodium alginate Into the aqueous phase solution, add the constantly stirring doxorubicin hydrochloride sol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an in-situ gelation chemotherapy and immunotherapy combined biopolymer pharmaceutical composition. The in-situ gelation chemotherapy and immunotherapy combined biopolymer pharmaceutical composition comprises a first component, a second component and a third component; the first component is alginate; the alginate can form porous gel with calcium ion in a body; the alginateis one or more of sodium alginate, potassium alginate and ammonium alginate; the second component is a chemotherapeutic drug capable of causing immungentic cell death; and the third component is an immunologic adjuvant. The in-situ gelation chemotherapy and immunotherapy combined biopolymer pharmaceutical composition belongs to a chemotherapy-immunotherapy pharmaceutical composition; therefore, anew anti-cancer pharmaceutical composition, which can take synergistic anticancer effect, reduce side effects, reduce the cancer metastasis probability and reduce the cancer recurrence probability, can be provided; and growth of a distal metastasis tumour and the tumour recurrence probability can be inhibited and reduced through immunoreaction while an in-situ tumour is killed effectively.

Description

technical field [0001] The invention relates to a pharmaceutical composition used for in-situ gelation chemotherapy and immune combination therapy, as well as a preparation method and application. Background technique [0002] The human immune system is a defense network covering the whole body. The first line of defense to protect the body is: skin, mucous membranes and their secretions, cell membranes, respiratory tract, gastrointestinal tract, urethra and kidneys; the second line of defense is: phagocytosis, antibacterial proteins and inflammatory response; the third line of defense is mainly composed of immune organs (tonsils, lymph nodes, thymus, bone marrow, and spleen, etc.) and immune cells (lymphocytes, phagocytes, etc.) with the help of blood circulation and lymphatic circulation. The main functions of the immune organs and immune cells are as follows: 1. Protection: resist the invasion of antigens, prevent the occurrence of diseases, and maintain the health of the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K9/19A61K39/39A61K47/36A61P35/00A61P35/04
CPCA61K9/0014A61K9/0024A61K9/19A61K39/39A61K45/00A61K47/36A61P35/00A61P35/04A61K2300/00
Inventor 刘庄巢宇赵琪
Owner SUZHOU INNOVATIVE BIOMATERIALS & PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com